Pipeline

Candidate
Discovery
Optimization
PoC
Preclinical
Phase 1
Phase 2
Phase 3
Systemic Sclerosis
AX-202
Lorem Ipsum Dolor
85%
Discovery
Optimization
PoC
Preclinical
Phase 1
Phase 2
Phase 3
Systemic Sclerosis
AX-202
Lorem Ipsum Dolor
85%
Candidate
Discovery
Optimization
PoC
Preclinical
Phase 1
Phase 2
Phase 3
Systemic Sclerosis
AX-202
Lorem Ipsum Dolor
85%
Undisclosed
AX-202
Lorem Ipsum Dolor
85%
Systemic Sclerosis

Systemic Sclerosis

Systemic sclerosis is a chronic, potentially life-threatening autoimmune disease which causes progressive fibrosis and tissue dysfunction in multiple organs. It carries the worst prognosis of all rheumatic diseases.
Disease epidemiology
  • Prevalence
    • 140 000 in US and EU5
  • Patient demographics:
    • Disease onset usually between 30 – 50 years
    • 80% of affected patients are female.
  • Disease classification
    • Limited cutaneous SSc: Fibrotic skin involvement restricted to the distal part of the limbs, overall slower progression of internal organ fibrosis
    • Diffuse cutaneous SSc: More extensive skin and internal organ involvement with more aggressive progression
Current treatment options
There are no approved therapies for overall disease control. Current therapeutic strategies show only modest and variable efficacy often accompanied by poor tolerability and potentially severe toxicities.
AX-202 scientific rationale
  • S100A4 is elevated both in lesional tissue and systemically in patients with SSc
  • Systemic S100A4 levels correlate with SSc disease activity, skin fibrosis and pulmonary function
  • AX-202 neutralizes the bioactivity of S100A4 both in vitro and in vivo
  • AX-202 successfully ameliorates fibrosis in both inflammatory and non-inflammatory models of skin fibrosis
Systemic Sclerosis
Organ Specific Fibrosis
Cancer

Systemic Sclerosis

Systemic sclerosis is a chronic, potentially life-threatening autoimmune disease which causes progressive fibrosis and tissue dysfunction in multiple organs. It carries the worst prognosis of all rheumatic diseases.
Candidate
Discovery
Optimization
PoC
Preclinical
Phase 1
Phase 2
Phase 3
Systemic Sclerosis
AX-104
Lorem Ipsum Dolor
85%
Disease epidemiology
  • Prevalence
    • 140 000 in US and EU5
  • Patient demographics:
    • Disease onset usually between 30 – 50 years
    • 80% of affected patients are female.
  • Disease classification
    • Limited cutaneous SSc: Fibrotic skin involvement restricted to the distal part of the limbs, overall slower progression of internal organ fibrosis
    • Diffuse cutaneous SSc: More extensive skin and internal organ involvement with more aggressive progression
Current treatment options
No approved therapy for overall disease control. Therapeutic strategies include off-label immunosuppressive drugs and management of symptoms and organ-specific complications.
AX104 scientific rationale

S100A4 is implicated as a key upstream trigger of the inflammatory and fibrotic pathways that drive disease progression.

  • S100A4 is elevated manifold both in the skin and systemically in patients with SSc; levels correlate with skin score and extent of organ involvement
  • Murine AX104 inhibits TGFb driven activation of fibroblasts

Murine AX104 successfully inhibits fibrosis in both inflammatory and non-inflammatory models of skin fibrosis.

Other Fibrotic Diseases

As cancers develop they enlist the assistance of the surrounding non-malignant cells to provide essential support for further growth. Tumor progression is profoundly influenced by these interactions with the tumor microenvironment which both determines the cancer cells ability to proliferate and spread and also shape the therapeutic response and resistance mechanisms.
Candidate
Discovery
Optimization
PoC
Preclinical
Phase 1
Phase 2
Phase 3
Organ Specific Fibrosis
AX-104
Lorem Ipsum Dolor
85%
AX104 scientific rationale
S100A4 is elevated in lesional tissue from patients with fibrosis where it acts as an upstream trigger of persistent inflammatory and fibrotic responses and contributes to unrestrained, self-sustaining fibroblast activation. Specifically, S100A4 has been shown to sensitize fibroblasts to the stimulatory effects of TGFbeta, drive epithelial-to-mesenchymal transition and modulate the release of inflammatory mediators and the overall immune response. S100A4 has been identified as an important actor in multiple fibrotic diseases, including lung, liver and kidney.

Cancer

As cancers develop they enlist the assistance of the surrounding non-malignant cells to provide essential support for further growth. Tumor progression is profoundly influenced by these interactions with the tumor microenvironment which both determines the cancer cells ability to proliferate and spread and also shape the therapeutic response and resistance mechanisms.
Candidate
Discovery
Optimization
PoC
Preclinical
Phase 1
Phase 2
Phase 3
Systemic Sclerosis
AX-104
Lorem Ipsum Dolor
85%
AX104 scientific rationale
S100A4 is a key player in the tumor microenvironment by triggering inflammatory responses and influencing the influx of non-resident immune and stromal cells. Consistent with this, multiple studies have found that patients which cancers express S100A4 have a more rapid progression, higher risk of metastases and an overall worse prognosis. Treatment with murine AX104 is associated with a counteraction of pro-tumorigenic immune responses, slower tumor growth and reduced risk of metastases.

Get in touch

    We are dedicated to developing transformative therapies for patients with fibrotic disease.
    We believe that AX-202 has the potential to transform how fibrosis is treated and help many patients poorly served by current therapeutic options.
    Arxx Therapeutics
    in Norway: Gaustadalléen 21, 0349 Oslo
    in Denmark: Symbion Science Park, Fruebjergvej 3, 2100 Copenhagen 
    © 2021 Arxx Therapeutics. All rights reserved. | Privacy Policy